Migraine is a disabling neurological disease, not simply a headache. It affects millions worldwide, causing significant disability and impacting daily life. The condition is associated with various neurological, sensory, and other symptoms, affecting the whole body. Understanding the complexities of migraine is crucial for effective diagnosis and treatment.
Pelago, a renowned digital clinic partnered with U.S. businesses and health plans for substance use management, recently announced the integration of cannabis into its specialized substance use disorder (SUD) treatments. This groundbreaking program, set to be fully implemented by Q3 2024, expands Pelago’s current digital substance use treatment solutions, which focus on tobacco, alcohol, and opioids. The program launch stems from Pelago’s recent $58 million funding round and marks the first large-scale digital cannabis use treatment program in the United States. Pelago’s cannabis program aims to address the rising prevalence of cannabis use disorders (CUDs) while simultaneously tackling the decline in treatment rates. By implementing evidence-based and clinically sound approaches, Pelago empowers individuals who use cannabis to understand its impact on their health and facilitates informed decision-making. The program leverages cognitive behavioral therapy and motivational enhancement therapy/interviewing at launch, with plans to incorporate contingency management in 2024.
Stress takes a toll not only on our minds but also our skin, manifesting as acne, eczema, and psoriasis. Psychodermatology explores the interplay between our emotions, stress levels, and skin health. This emerging field complements traditional dermatological treatments, addressing psychological factors that may contribute to skin issues. Cognitive behavioral therapy, lifestyle changes, and relaxation techniques can empower patients to manage stress and improve their skin conditions.
